The CMA has imposed over £100 million in fines after Advanz inflated the price of thyroid tablets, causing the NHS and patients to lose out. Following an investigation, the Competition and Markets Authority (CMA) has found that from 2009 until 2017 the pharmaceutical company Advanz charged the NHS excessive and unfair prices for supplying liothyronine […]
The post Pharma firm fined over pricing of crucial thyroid drug and ripping off the NHS appeared first on Euro Weekly News Spain.
